Clinical Trials Directory

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. This study aims to test the use of the drug ondansetron to reduce the symptoms associated with opioid withdrawal and to prevent the progression of opioid physical dependence, thereby allowing future investigators to better test the role of physical dependence in the development of addiction and also possibly improving acceptance of abstinence-based programs for addiction.

Stanford is now accepting new patients for this trial. Please contact Larry Chu, MD, MS at 650-724-2970 for more information.



  • drug : Ondansetron

Phase: N/A


Ages Eligible For Study:

18 Years - 60 Years

Inclusion Criteria

- Diagnosis of chronic low-back pain and who may be taking up to 30 mg equivalent of morphine per day (such as Vicodin, Percocet, etc) - 18-60 years old - Eligible to escalate opioid therapy dose, as determined by the treating physician or PI - At low risk for addiction as determined by the PI and an addiction expert, Dr. Ian Carroll.

External Links

Contact information

Primary Contact:

Larry Chu, MD, MS 650-724-2970

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: